Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02561234 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Aeglea Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT02561234 is a Phase 1 study that has completed, run by Aeglea Biotherapeutics. The registered enrollment target is 98 participants.
The verdict
NCT02561234, a Phase 1 study, has completed, sponsored by Aeglea Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
This is the first-in-human study of the safety of increasing dose levels of AEB1102 in patients with advanced cancers. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and tumor growth.
Interventions
- DRUG Co-ArgI-PEG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02561234
The ClinicalTrials.gov registry entry for NCT02561234 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aeglea Biotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Co-ArgI-PEG is the first listed.
NCT02561234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02561234 about?
NCT02561234 is a clinical study titled "A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors". This is the first-in-human study of the safety of increasing dose levels of AEB1102 in patients with advanced cancers. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and tumor growth.
What is the current status of trial NCT02561234?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2015-10. Estimated completion is 2019-05.
What interventions are being tested in trial NCT02561234?
The interventions under investigation include: Co-ArgI-PEG (DRUG).
Who is sponsoring clinical trial NCT02561234?
This trial is sponsored by Aeglea Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.